Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Riluzole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 4/20 | 1.00 |
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riluzole SCHEMBL29359189 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL5053829 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL78905 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL29079504 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL29079505 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL23610347 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL27787859 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL1394245 | 0.98 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL4443848 | 0.90 | RAB9A (0.82) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL9218955 | 0.89 | CYP3A4 (0.80) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5656647-A | ADMINISTERING; USEFUL IN X-RAY THERAPY, EXPOSURE TO NUCLEAR RADITION AND ANTICARCINOGENIC AGENTS | RHONE-POULENC RORER S.A. (FR) | 1997-08-12 | — | — | US | disclosed |